| 25A587 |
Novartis Pharmaceuticals Corporation v. Robert F. Kennedy, Secretary of Health and Human Services, et al. |
Third Circuit |
2025-11-18 |
Application |
|
certiorari consumer-protection extension pharmaceutical regulatory time-limit |
Question not identified. |
| 19-584 |
Nuvo Pharmaceuticals (Ireland) Designated Activity Company, et al. v. Dr. Reddy's Laboratories Inc., et al. |
Federal Circuit |
2019-11-04 |
Denied |
Response Waived |
35-usc-112 enablement federal-circuit innovation patent patent-law pharmaceutical pharmaceutical-composition prior-art written-description |
Whether the Federal Circuit erred by holding that, whenever the prior art teaches away from a pharmaceutical composition, the written description of a… |
| 18-1502 |
Brian Mark Burmaster v. Eli Lilly and Company |
Sixth Circuit |
2019-06-03 |
Denied |
|
6th-amendment civil-rights constitutional-rights drug-marketing due-process free-speech government-action government-intervention government-overreach government-regulation medical-ethics pharmaceutical pharmaceutical-liability pharmaceutical-litigation sixth-amendment |
If a company's manufactured and marketed product, such as Eli Lilly's Zyprexa is cited by the US Government Quack (called a medical doctor?) as the mi… |
| 18-441 |
Accord Healthcare, Inc., et al. v. UCB, Inc., et al. |
Federal Circuit |
2018-10-09 |
Denied |
Amici (1)Response Waived |
35-usc-103 lead-compound obviousness patent patent-invalidation patent-law pharmaceutical pharmaceutical-compound prior-art |
Did the Federal Circuit commit error in holding that a patent claim to an obvious modification of a prior art compound was not invalid as obvious unde… |
| 18-182 |
AIDS Healthcare Foundation, Inc. v. Gilead Sciences, Inc., et al. |
Federal Circuit |
2018-08-09 |
Denied |
Response Waived |
actual-controversy article-iii declaratory-judgment drug-exclusivity fda-approval generic-drugs patent-invalidity pharmaceutical pharmaceutical-patents standing |
In the context of patent cases involving pharmaceutical products, does the "actual controversy" requirement of the Declaratory Judgment Act, 28 U.S.C.… |